Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Avinger Price Performance
Shares of NASDAQ:AVGR traded up $0.03 on Friday, hitting $1.74. The company's stock had a trading volume of 170,092 shares, compared to its average volume of 144,607. The company has a market capitalization of $9.88 million, a PE ratio of -0.30 and a beta of 1.68. The company has a debt-to-equity ratio of 1.24, a current ratio of 4.67 and a quick ratio of 3.78. Avinger has a 1 year low of $1.40 and a 1 year high of $19.26. The company has a 50-day simple moving average of $1.55 and a 200 day simple moving average of $3.36.
Avinger (NASDAQ:AVGR - Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The medical device company reported ($2.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.21) by ($1.12). The firm had revenue of $1.89 million for the quarter, compared to analysts' expectations of $1.89 million. Avinger had a negative net margin of 219.16% and a negative return on equity of 183.34%. During the same period in the prior year, the business posted ($1.40) earnings per share. Sell-side analysts forecast that Avinger will post -4.97 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have commented on AVGR. StockNews.com began coverage on Avinger in a research note on Thursday. They issued a "sell" rating for the company. B. Riley cut their target price on Avinger from $11.00 to $9.00 in a research note on Wednesday, May 11th.